



S2427 (BRIGHT Trial) Kickoff

S2427 BRIGHT: The next stage in bladder preservation trials

If a patient's muscle-invasive bladder cancer responds completely to neoadjuvant therapy, can radiation therapy plus immunotherapy help them keep their bladder?

FRIDAY, SEPT 19 • 4:15 – 5:15 PM CT • COMISKEY (CONCOURSE LEVEL)

Pre-registration, patients get standard-of-care neoadjuvant therapy followed by TURBT with systematic biopsies. Patients with cT0 or cT1 disease at that time may be eligible to enroll.

S2427 participants get radiation therapy plus 12 months of pembrolizumab

Primary endpoint: 3-year bladder-intact event-free survival (BI-EFS)

S2427 BRIGHT activates in early September! Its enrollment goal is 111 patients.

WE NEED YOU AND YOUR INSTITUTION TO MAKE THIS TRIAL A SUCCESS!

Attend the S2427 Kickoff
to learn more and get answers to your questions.

STUDY CHAIR



*Leslie Ballas,
MD*



*Siamak
Daneshmand,
MD*



*Abhishek
Tripathi, MD*



*Daniel A.
Hamstra,
MD, PhD*



*James B. Yu,
MD, MHS*

CO-CHAIRS

BIostatisticians



Sam Callis, MS



*Catherine
Tangen, DrPH*

PATIENT ADVOCATE



*Darrell
Nakagawa*